b-AP15 (formerly known as NSC687852; b-AP15; USP14 Inhibitor III; b-AP-15; NSC-687852) is a novel, potent and specific deubiquitinase (DUB) inhibitor of 19S proteasomes activity of Ub-AMC cleavage with potential antineoplastic activity.

LDN-57444 (LDN57444; LDN 57444) is a potent, reversible, and competitive proteasome inhibitor for Uch-L1 (ubiquitin C-terminal hydrolase-L1) with the potential to treat PD-Parkinson’s disease.

SJB2-043, a C527 analog, is a novel and potent inhibitor of USP1/UAF1 (ubiquitin-specific protease 1/Usp1-associated Factor 1) complex with IC50 of 544 nM.

TCID (4,5,6,7-tetrachloro-1H-indene-1,3(2H)-dione) is a novel and potent DUB (deubiquitinylating enzymes) inhibitor that inhibits ubiquitin C-terminal hydrolase L3 with an IC50 of 0.6 μM.

NSC632839 is a nonselective isopeptidase inhibitor that inhibits USP2, USP7, and SENP2 with EC50 values of 45±4 μM, 37±1 μM, and 9.8±1.8 μM, respectively.

VLX1570 is a competitive inhibitor of the 19S proteasome-specific DUB (deubiquitylating enzymes) activity with IC50 ranging from 4.2 uM to 8.6 uM.

GNE-6776 (GNE6776) is a novel, highly potent, specific, non-covalent, and orally bioavailable USP7 (Ubiquitin specific proteases7) inhibitor with anticancer activity.

IU1 (IU-1; IU 1) is a cell-permeable, reversible and selective proteasome inhibitor of human USP14 with the potential to be used for treating neurodegenerative disease.

EOAI3402143 (EOAI 3402143; EOAI-3402143) is a novel and potent inhibitor of Usp9x, Usp24 and deubiquitinase (DUB) with potential anticancer activity.

P5091 (also called P5091; P-005091; P-5091; P005091) is a novel, potent, specific and selective inhibitor of ubiquitin-specific protease 7 (USP7) with potential anticancer activity.